4D Molecular Therapeutics (NASDAQ:FDMT) Given Sell (E+) Rating at Weiss Ratings
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “sell (e+)” rating reiterated by research analysts at Weiss Ratings in a research note issued to investors on Thursday,Weiss Ratings reports. Other analysts have also recently issued reports about the company. Royal Bank of Canada reduced their price target on 4D Molecular Therapeutics from […]
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “sell (e+)” rating reiterated by research analysts at Weiss Ratings in a research note issued to investors on Thursday,Weiss Ratings reports. Other analysts have also recently issued reports about the company. Royal Bank of Canada reduced their price target on 4D Molecular Therapeutics from […]
